Procyon Cat HCChlam / PFeLV Lyophilisate and Solvent for Suspension for Injection
Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Summary of Product characteristics
(SPC)
11-12-2009
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
Chlamydophila felis, Feline calicivirus, Feline leukemia virus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Available from:
Schering-Plough Ltd
ATC code:
QI06AJ04
INN (International Name):
Chlamydophila felis, Feline calicivirus, Feline leukemia virus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Authorization status:
Expired
Summary of Product characteristics
Issued 11/12/2009 – AN 00841/2007
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Procyon Cat
HCChlam/PFeLV
Lyophilisate and solvent for suspension for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
i.
HCChlam – freeze dried fraction
Names of substances
Quantity per dose
(reconstituted)
(log
10
TCID
50
/mL
1
)
Active ingredients
Live, attenuated:
Feline Rhinotracheitis virus (F2 strain)
≥ 4.9
Feline Calicivirus (F-9 strain)
≥ 4.4
Feline Pneumonitis (Baker Strain)
(
_Chlamydophila_
_ felis_)
≥ 3.4
ii.
PFeLV – liquid diluent fraction
Names of substances
Quantity per 1 ml dose
Active ingredients
Inactivated:
Feline Panleucopenia Virus (Dow 13-001
strain)
≥ 7.13 log
2
SNT
2
Feline Leukaemia Virus (Rickard strain)
≥ 1.0 RP
3
Adjuvant
Carbopol 981 solution
20% v/v
1
Tissue Culture Infective Dose
2
Value in Guinea Pig Potency Test
3
Relative Potency Units are derived from ELISA
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of cats from 8 weeks of age.
To reduce clinical signs and shedding caused by infection with Feline Rhinotracheitis
virus (FVR), Feline Calicivirus (FCV) and Feline Pneumonitis (FPN).
To provide protection against Feline Panleucopenia (FPL).
To prevent persistent viraemia caused by infection with Feline Leukaemia Virus
(FeLV).
1/4
Issued 11/12/2009 – AN 00841/2007
Immunity has been demonstrated following completion of the primary vaccination course at:
2 weeks for FeLV, 3 weeks for FPL and 4 weeks for FVR, FCV and FPN.
Duration of immunity has been demonstrated following completion of the primary course for
at least: 4 years for FPL, 3 y
Read the complete document
